==========================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Earliest Event Reported: April 19, 1999
MEDICIS PHARMACEUTICAL CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 0-18443 52-1574808
(State or other (Commission (IRS Employer
jurisdiction of file number) Identification No.)
incorporation)
4343 East Camelback Road
Phoenix, Arizona 85018
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code:
(602) 808-8800
(Former Name or Former Address, if Changed Since Last Report)
==========================================================================
Item 5. Other Events
Effective as of April 1, 1999, the Registrant purchased all the issued
and outstanding common stock of Ucyclyd Pharma, Inc. ("Ucyclyd"), a
Maryland corporation (the "Acquisition") pursuant to a Stock Purchase
Agreement by and among the Registrant, Ucyclyd and the Sellers signatory
thereto. A description of the Acquisition is contained in the press
release attached hereto as Exhibit 99.1 and incorporated herein by
reference.
Item 7. Financial Statements and Exhibits
(c) Exhibits
The following Exhibits are filed as part of this report:
99.1 - Press Release dated April 19, 1999.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
MEDICIS PHARMACEUTICAL CORPORATION
/S/ MARK A. PRYGOCKI, SR.
-----------------------------------
Mark A. Prygocki, Sr.
Chief Financial Officer
Date: April 22, 1999.
EXHIBIT INDEX
Exhibit
Number Description
- ------- -----------
99.1 -- Press Release dated April 19, 1999.